Natera (NTRA) announced the launch of the TEODOR trial. TEODOR is a Phase II, multicenter, randomized controlled trial that aims to replace chemotherapy with endocrine therapy prior to surgery for a subset of women with hormone receptor-positive, HER2-negative breast cancer, who are endocrine responsive and test negative with Signatera.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA: